HC Wainwright Has Positive Estimate for TRVI Q2 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.11) per share for the quarter, up from their previous forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.09) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

Several other equities research analysts also recently issued reports on TRVI. Morgan Stanley reiterated an “overweight” rating and set a $20.00 price target on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a research report on Friday, April 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. Finally, Needham & Company LLC dropped their price objective on Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $21.70.

Trevi Therapeutics Stock Down 1.5%

NASDAQ TRVI opened at $14.05 on Friday. The business has a 50 day moving average price of $12.69 and a 200-day moving average price of $11.95. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -43.91 and a beta of 1.07.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its position in Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after acquiring an additional 2,996 shares during the last quarter. KBC Group NV purchased a new position in shares of Trevi Therapeutics in the 1st quarter valued at approximately $29,000. Hilton Head Capital Partners LLC purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $50,000. Finally, Strs Ohio purchased a new position in shares of Trevi Therapeutics in the 1st quarter valued at approximately $52,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics News Summary

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Management said the company’s cash runway now extends into 2030, which investors interpreted as reducing near‑term dilution risk and supported buying interest. Article Title
• Positive Sentiment: HC Wainwright and Needham reaffirmed “Buy” ratings; HC Wainwright kept a $21 target while Needham trimmed its target slightly to $23 — both signal continued analyst conviction despite some model changes. Article Title Article Title
• Neutral Sentiment: Q1 2026 earnings call transcripts were released (useful for parsing management commentary on clinical programs, cash runway and milestones). These are informational and may influence sentiment as investors dig into details. InsiderMonkey Transcript Seeking Alpha Transcript
• Negative Sentiment: Q1 results included an EPS miss (reported loss per share bigger than consensus), which refreshed concerns about near‑term profitability and pressured the stock. Management commentary and the call will determine how persistent those concerns are. Earnings Transcript
• Negative Sentiment: HC Wainwright trimmed its FY2030 EPS projection from $0.79 to $0.70 — a downward revision to long‑term expectations that can cap valuation upside even though the firm retained a Buy rating. MarketBeat TRVI

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.